Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)
China · Delayed Price · Currency is CNY 12.92
+0.41 (3.28%)
May 20, 2026, 2:15 PM CST
SHA:603439 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,675 | 1,702 | 2,144 | 1,634 | 1,201 | 938.84 |
Other Revenue | 0.86 | 0.86 | 0.55 | 0.51 | 0.33 | 0.13 |
| 1,676 | 1,703 | 2,144 | 1,635 | 1,201 | 938.97 | |
Revenue Growth (YoY) | -21.35% | -20.59% | 31.16% | 36.10% | 27.94% | 48.99% |
Cost of Revenue | 486.76 | 519.33 | 652.98 | 437.99 | 339.52 | 277.07 |
Gross Profit | 1,189 | 1,184 | 1,491 | 1,197 | 861.8 | 661.89 |
Selling, General & Admin | 951.13 | 948.3 | 1,089 | 879.21 | 618.01 | 492.75 |
Research & Development | 22.87 | 27.91 | 46.5 | 30.61 | 17.86 | 7.68 |
Other Operating Expenses | 25.92 | 26.81 | 17.31 | 16.6 | 11.01 | 8.56 |
Operating Expenses | 998.52 | 997.45 | 1,163 | 929.77 | 657.18 | 509.98 |
Operating Income | 190.7 | 186.06 | 328.34 | 267.22 | 204.62 | 151.92 |
Interest Expense | -12.64 | -11.07 | -14.61 | -4.13 | -5.24 | -8.34 |
Interest & Investment Income | 3.28 | 3.96 | 5.8 | 60.13 | 17.56 | 25.81 |
Other Non Operating Income (Expenses) | -0.61 | -0.05 | -0.37 | 1.89 | -0.21 | -0.09 |
EBT Excluding Unusual Items | 180.74 | 178.89 | 319.16 | 325.1 | 216.74 | 169.29 |
Impairment of Goodwill | -121.98 | -121.98 | - | - | -0.08 | - |
Gain (Loss) on Sale of Investments | -2.61 | -2.62 | 0.15 | - | -0.09 | - |
Gain (Loss) on Sale of Assets | -0.29 | -0.12 | -0.17 | 0.59 | -0.09 | -0.15 |
Asset Writedown | 1.82 | -0.03 | -0.57 | -0.05 | -0.1 | -0.01 |
Other Unusual Items | 13.62 | 13.62 | 6.47 | 8.38 | 6.18 | 7.51 |
Pretax Income | 71.29 | 67.77 | 325.03 | 334.02 | 222.56 | 176.65 |
Income Tax Expense | 20.54 | 19.61 | 45.19 | 39.15 | 30.62 | 28.05 |
Earnings From Continuing Operations | 50.75 | 48.15 | 279.84 | 294.87 | 191.94 | 148.6 |
Minority Interest in Earnings | -2.04 | -1.9 | -5.81 | -2.17 | 9.35 | 3.68 |
Net Income | 48.72 | 46.25 | 274.03 | 292.7 | 201.28 | 152.28 |
Net Income to Common | 48.72 | 46.25 | 274.03 | 292.7 | 201.28 | 152.28 |
Net Income Growth | -81.26% | -83.12% | -6.38% | 45.42% | 32.18% | 62.08% |
Shares Outstanding (Basic) | 417 | 420 | 409 | 412 | 411 | 412 |
Shares Outstanding (Diluted) | 417 | 420 | 409 | 412 | 411 | 412 |
Shares Change (YoY) | 0.67% | 2.81% | -0.79% | 0.36% | -0.19% | 5.14% |
EPS (Basic) | 0.12 | 0.11 | 0.67 | 0.71 | 0.49 | 0.37 |
EPS (Diluted) | 0.12 | 0.11 | 0.67 | 0.71 | 0.49 | 0.37 |
EPS Growth | -81.38% | -83.58% | -5.63% | 44.90% | 32.43% | 54.17% |
Free Cash Flow | 167.36 | 138.74 | 61.87 | 167.97 | 173.38 | 128.96 |
Free Cash Flow Per Share | 0.40 | 0.33 | 0.15 | 0.41 | 0.42 | 0.31 |
Dividend Per Share | 0.060 | 0.060 | 0.340 | 0.200 | 0.100 | - |
Dividend Growth | -82.35% | -82.35% | 70.00% | 100.00% | - | - |
Gross Margin | 70.96% | 69.50% | 69.55% | 73.21% | 71.74% | 70.49% |
Operating Margin | 11.38% | 10.93% | 15.31% | 16.34% | 17.03% | 16.18% |
Profit Margin | 2.91% | 2.72% | 12.78% | 17.90% | 16.75% | 16.22% |
Free Cash Flow Margin | 9.99% | 8.15% | 2.89% | 10.27% | 14.43% | 13.73% |
EBITDA | 262.97 | 258.84 | 403.16 | 303.64 | 220.44 | 163.09 |
EBITDA Margin | 15.69% | 15.20% | 18.80% | 18.57% | 18.35% | 17.37% |
D&A For EBITDA | 72.27 | 72.78 | 74.82 | 36.42 | 15.82 | 11.17 |
EBIT | 190.7 | 186.06 | 328.34 | 267.22 | 204.62 | 151.92 |
EBIT Margin | 11.38% | 10.93% | 15.31% | 16.34% | 17.03% | 16.18% |
Effective Tax Rate | 28.81% | 28.94% | 13.90% | 11.72% | 13.76% | 15.88% |
Revenue as Reported | 1,676 | 1,703 | 2,144 | 1,635 | 1,201 | 938.97 |
Advertising Expenses | - | 0.21 | 1.47 | 1.78 | 2.29 | 0.01 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.